Veterinary MedicineImmunologyPathologyImmunology Of Infectious DiseasesInnate ImmunityMucosal ImmunologyGastrointestinal ImmunologyGastrointestinal InflammationImmunopathology Of Parasitic DiseaseImmunoregulation In Parasitic InfectionMucosal Immune SystemMucosal ImmunityHost Immune Response To Intestinal ParasitesInnate Responses To HelminthsIntestinal Mucosal ImmunityIntestinal ParasitosisMucosal Immune Responses To PathogensPathogenesis Of Intestinal Parasitic DiseaseProtective TreatmentsStrongyloides Infections
Information about interleukin-3 (IL-3) effects in vivo is limited compared with the in vitro effects. We found that a repetitive injection of a low dose of recombinant IL-3 induced protection against intestinal worms of Strongyloides ratti in C57BL/6 mice. When mice were injected i.p. with different doses of recombinant IL-3 twice a day from day -5 to day -1 and infected orally with larvae recovered from the head of infected rats on day 0, worm recovery from the small intestine was markedly reduced by a total of 10(4) U IL-3 or more on day 2 post-infection. The number of intestinal mucosal mast cells (MMC) was increased by the protective dose of IL-3. The IL-3 treatment, however, was ineffective in protecting mice against tissue migrating larvae, as assessed by recovery from the head. The protective effect of IL-3 on intestinal worms was observed within 6 hr post oral infection, suggesting little concern with antigen-specific immune responses. The effective dose of IL-3 treatment increased the number of MMC progenitors five times in the spleen and the mesenteric lymph nodes. An MMC-specific protease, MMCP-1, was secreted 200 times more than in controls in the intestinal lumen by the IL-3 treatment. The IL-3 treatment induced no protection or mastocytosis in mast cell-deficient W/Wv mice. These results suggest that the IL-3-induced intestinal protection against S. ratti is mediated by MMC.
19